Piper Sandler Cuts Alnylam Price Target to $410 From $489
Piper Sandler lowered its price target for Alnylam Pharmaceuticals to $410 from $489.
Related stories
Microsoft Shares Hit 4-week Low
Microsoft shares decreased to 515.68 USD, the lowest since October 2026. Over the past 4 weeks, Microsoft gained 1.2%, and in the last 12 months, it decreased 1.27%.
L impact | EQUITY | Oct 30, 2026, 01:36 PM UTC
Exxon CEO Woods Expects Over $100 Billion in Capex Through 2030
M impact | EQUITY | Oct 30, 2026, 01:35 PM UTC
Church & Dwight Reports Q3 2026 Revenue of $1.60 Billion
Church & Dwight's Q3 2026 revenue rose 1% year over year to $1.60 billion, above Wall Street expectations. Its next-quarter revenue guidance of $1.64 billion was 1.4% below analyst
M impact | EQUITY | Oct 30, 2026, 01:35 PM UTC
Lockheed Martin Shares Hit 32-week High
Lockheed Martin shares increased to 650.03 USD, the highest since March 2026. Over the past 4 weeks, Lockheed Martin gained 27.24%, and in the last 12 months, it increased 32.32%.
L impact | EQUITY | Oct 30, 2026, 01:34 PM UTC
Nasdaq Composite Falls 633.70 Points (2.42%)
M impact | EQUITY | Oct 30, 2026, 01:33 PM UTC
S&P 500 Falls 96.23 Points, or 1.25%
M impact | EQUITY | Oct 30, 2026, 01:33 PM UTC